Table 1.
Patient characteristics.
| n = 61 | |
|---|---|
| Median age at diagnosis (years) | 20.9 (5–39) |
| Age < 10 | 3 (4.9%) |
| Age 10–19 | 25 (41.0%) |
| Age 20–29 | 22 (36.1%) |
| Age 30–39 | 11 (18.0%) |
| Histology | |
| Dysgerminoma | 11 (18.0%) |
| Immature teratoma | 16 (26.2%) |
| Yolk sac tumor | 11 (18.0%) |
| Mixed | 23 (37.7%) |
| FIGO stage | |
| I | 32 (52.5%) |
| II | 0 (0%) |
| III | 22 (36.1%) |
| IV | 7 (11.5%) |
| β-hCG | (n = 38) |
| Elevated | 14 (36.8%) |
| Median (range), mIU/mL | 116.6 (3.1–16,000) |
| Not elevated | 24 (63.2%) |
| AFP | (n = 44) |
| Elevated | 29 (65.9%) |
| Median (range), U/mL | 15,374 (16.6–360,186) |
| Not elevated | 15 (34.1%) |
| CA125 | (n = 47) |
| Elevated | 43 (91.5%) |
| Median (range), U/mL | 232 (39.3–1924) |
| Not elevated | 4 (8.5%) |
| CA19-9 | (n = 34) |
| Elevated | 7 (20.6%) |
| Median (range), U/mL | 90 (56.8–664) |
| Not elevated | 27 (79.4%) |
| Surgery | |
| Upfront surgery only | 51 (83.6%) |
| Biopsy + delayed surgery | 3 (4.9%) |
| Upfront surgery + salvage surgery | 7 (11.5%) |
| First-line chemotherapy | |
| bEP | 26 (42.6%) |
| BEP | 11 (18.0%) |
| CybEP | 18 (29.5%) |
| CyBEP | 2 (3.3%) |
| Others | 2 (3.3%) |
| No chemotherapy | 2 (3.3%) |
AFP, alpha fetoprotein; BEP, bleomycin 30 units per week + etoposide + cisplatin; bEP, bleomycin 15 units/m2 on day 1 + etoposide + cisplatin; b-hCG, beta-human chorionic gonadotropin; CA-125, cancer antigen 125, CA-19-9, cancer antigen 19-9; CybEP, cyclophosphamide + bleomycin 15 units/m2 on day 1 + etoposide + cisplatin, CyBEP, cyclophosphamide + bleomycin 30 units per week + etoposide + cisplatin; FIGO, Fédération Internationale de Gynécologie et d’Obstétrique.